GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr N Hirons |
|||
b) |
Position/status |
SVP, Global Ethics and Compliance |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.0000 |
15,914 (Deferred) |
|
||
|
£0.0000 |
9,392 (Matching) |
|
||
|
|
|
|
||
d) |
Aggregated information |
|
|||
Aggregated volume Price |
25,306 £0.0000 |
||||
e) |
Date of the transaction |
2019-02-15 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
a) |
Name |
Mr N Hirons |
|
|||
b) |
Position/status |
SVP, Global Ethics and Compliance |
|
|||
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
a) |
Name |
GlaxoSmithKline plc |
|
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£15.9006 |
7,500 (Deferred) |
|
|||
|
£15.9006 |
4,425 (Matching) |
|
|||
|
|
|
|
|||
d) |
Aggregated information |
|
|
|||
Aggregated volume Price |
11,925 £15.9006 |
|
||||
e) |
Date of the transaction |
2019-02-15 |
|
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Redfern |
|||
b) |
Position/status |
Chief Strategy Officer |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.0000 |
20,254 (Deferred) |
|
||
|
£0.0000 |
11,952 (Matching) |
|
||
|
|
|
|
||
d) |
Aggregated information |
|
|||
Aggregated volume Price |
32,206 £0.0000 |
||||
e) |
Date of the transaction |
2019-02-15 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
a) |
Name |
Mr D Redfern |
|
|||
b) |
Position/status |
Chief Strategy Officer |
|
|||
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
a) |
Name |
GlaxoSmithKline plc |
|
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£15.878 |
9,545 (Deferred) |
|
|||
|
£15.878 |
5,631 (Matching) |
|
|||
|
|
|
|
|||
d) |
Aggregated information |
|
|
|||
Aggregated volume Price |
15,176 £15.878 |
|
||||
e) |
Date of the transaction |
2019-02-15 |
|
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms C Thomas |
|||
b) |
Position/status |
SVP, Human Resources |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.0000 |
29,636 (Deferred) |
|
||
|
£0.0000 |
17,488 (Matching) |
|
||
|
|
|
|
||
d) |
Aggregated information |
|
|||
Aggregated volume Price |
47,124 £0.0000 |
||||
e) |
Date of the transaction |
2019-02-15 |
|||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms C Thomas |
|||
b) |
Position/status |
SVP, Human Resources |
|||
c) |
Initial notification/ amendment |
Initial Notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£15.8753 |
13,951 (Deferred) |
|
||
|
£15.8753 |
8,232 (Matching) |
|
||
|
|
|
|
||
d) |
Aggregated information |
|
|||
Aggregated volume Price |
22,183 £15.8753 |
||||
e) |
Date of the transaction |
2019-02-15 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |